Page last updated: 2024-11-02

oxonic acid and Vomiting

oxonic acid has been researched along with Vomiting in 19 studies

Oxonic Acid: Antagonist of urate oxidase.

Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.

Research Excerpts

ExcerptRelevanceReference
"Gemcitabine plus cisplatin (GC) is the standard treatment of advanced biliary tract cancer (BTC); however, it causes nausea, vomiting, and anorexia, and requires hydration."9.30Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. ( Asagi, A; Fukutomi, A; Furuse, J; Hara, H; Hosokawa, A; Ikeda, M; Ioka, T; Ishii, H; Iwai, T; Kamata, K; Katayama, H; Kato, N; Kawabe, K; Kawamoto, Y; Kojima, Y; Miyakawa, H; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nakamori, S; Nakamura, K; Okano, N; Okusaka, T; Ozaka, M; Shimizu, K; Shioji, K; Sugimori, K; Sugimoto, R; Tobimatsu, K; Ueno, M; Wada, K; Yamaguchi, H; Yamashita, T; Yanagimoto, H; Yane, K; Yukisawa, S, 2019)
"Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)."9.24A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017)
"Palonosetron was not superior to granisetron in combination antiemetic therapy."5.43Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. ( Fujimura, T; Fushida, S; Kadoya, N; Kaji, M; Kinami, S; Kinoshita, J; Nezuka, H; Ohta, T; Ohyama, S; Oyama, K; Takai, Y; Takeda, T; Tsuji, K; Tsukada, T; Tsukioka, Y; Yabushita, K, 2016)
"Gemcitabine plus cisplatin (GC) is the standard treatment of advanced biliary tract cancer (BTC); however, it causes nausea, vomiting, and anorexia, and requires hydration."5.30Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. ( Asagi, A; Fukutomi, A; Furuse, J; Hara, H; Hosokawa, A; Ikeda, M; Ioka, T; Ishii, H; Iwai, T; Kamata, K; Katayama, H; Kato, N; Kawabe, K; Kawamoto, Y; Kojima, Y; Miyakawa, H; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nakamori, S; Nakamura, K; Okano, N; Okusaka, T; Ozaka, M; Shimizu, K; Shioji, K; Sugimori, K; Sugimoto, R; Tobimatsu, K; Ueno, M; Wada, K; Yamaguchi, H; Yamashita, T; Yanagimoto, H; Yane, K; Yukisawa, S, 2019)
"Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC)."5.24A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer. ( Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M, 2017)
"Previous studies have shown sex-related differences in the incidence of adverse events following treatment with fluoropyrimidines, however the mechanism of this difference is unknown."2.90Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer. ( Amagai, K; Chin, K; Fujii, H; Fuse, N; Gotoh, M; Hironaka, S; Hyodo, I; Imamura, H; Koizumi, W; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H, 2019)
"The purpose of this phase I study of the dose escalation of oxaliplatin in combination with oral S-1 and pelvic radiation preoperatively for poor-risk lower rectal cancer was to determine the dose-limiting toxicity (DLT) and recommended dose of oxaliplatin."2.80A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis. ( Fujita, S; Hamaguchi, T; Ito, Y; Kinugasa, Y; Moriya, Y; Noura, S; Ohue, M; Saito, N; Sakai, D; Shimada, Y, 2015)
" Major adverse effects were hematological toxicities, gastrointestinal disturbance, neurosensory toxicity."2.76[Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer]. ( Jin, ZM; Zhu, QC, 2011)
" Pharmacokinetic analyses were performed following a single dose of S-1 on D-5 and D1 of the first cycle."2.75Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. ( Bae, KS; Chang, HM; Jang, G; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Park, I; Ryu, MH; Sym, SJ; Yoo, C, 2010)
"Gemcitabine plus S-1 is a viable treatment alternative to gemcitabine, which is one of the standard treatments in patients with LAPC."1.46Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. ( Furuse, J; Hamada, C; Ikari, T; Imai, S; Isayama, H; Ishii, H; Nakai, Y; Okamura, S; Okusaka, T, 2017)
"Palonosetron was not superior to granisetron in combination antiemetic therapy."1.43Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. ( Fujimura, T; Fushida, S; Kadoya, N; Kaji, M; Kinami, S; Kinoshita, J; Nezuka, H; Ohta, T; Ohyama, S; Oyama, K; Takai, Y; Takeda, T; Tsuji, K; Tsukada, T; Tsukioka, Y; Yabushita, K, 2016)
" With regard to adverse events, the rates of nausea (p<0."1.42[A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer]. ( Funazaki, H; Ikeda, M; Katayama, S; Kobayashi, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ochiai, A; Ohno, I; Okusaka, T; Okuyama, H; Sakamoto, Y; Shimizu, S; Takahashi, H; Tanaka, H; Ueno, H, 2015)
" Severe adverse events were observed in 22 patients (91."1.42Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck. ( Honda, K; Ishikawa, K; Sato, T; Suzuki, S; Yamazaki, K, 2015)
"In 62 gastric cancer patients treated with S-1 alone, data relating to the occurrence of gastrointestinal toxicity (diarrhea, vomiting, and nausea) and possible contributing factors were retrospectively collected, and logistic regression analysis was performed."1.40Reduction in gastrointestinal toxicity by gastric secretion inhibitors during S-1 monotherapy for patients with gastric cancer. ( Chisaki, Y; Hira, D; Morita, SY; Noda, S; Terada, T; Yano, Y, 2014)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (5.26)18.2507
2000's0 (0.00)29.6817
2010's17 (89.47)24.3611
2020's1 (5.26)2.80

Authors

AuthorsStudies
Kobayashi, S1
Ueno, M2
Ogawa, G1
Fukutomi, A2
Ikeda, M3
Okusaka, T4
Sato, T2
Ito, Y2
Kadota, T1
Ioka, T2
Sugimori, K2
Sata, N1
Nakamori, S2
Shimizu, K3
Mizuno, N2
Ishii, H3
Furuse, J4
Morizane, C2
Mizusawa, J1
Katayama, H1
Ozaka, M1
Okano, N2
Hara, H1
Yanagimoto, H1
Wada, K1
Tobimatsu, K1
Yane, K1
Yamaguchi, H2
Asagi, A1
Yukisawa, S1
Kojima, Y1
Kawabe, K1
Kawamoto, Y1
Sugimoto, R1
Iwai, T1
Nakamura, K1
Miyakawa, H1
Yamashita, T1
Hosokawa, A1
Kato, N1
Shioji, K1
Nakagohri, T1
Kamata, K1
Fang, M1
Song, T1
Liang, X1
Lv, S1
Li, J1
Xu, H1
Luo, L1
Jia, Y1
Hamada, C1
Ikari, T1
Isayama, H1
Nakai, Y1
Imai, S1
Okamura, S1
Wang, F1
Fan, QX1
Wang, HH1
Han, DM1
Song, NS1
Lu, H1
Yamada, Y1
Koizumi, W1
Nishikawa, K1
Gotoh, M1
Fuse, N1
Sugimoto, N1
Nishina, T1
Amagai, K1
Chin, K1
Niwa, Y1
Tsuji, A1
Imamura, H1
Tsuda, M1
Yasui, H2
Fujii, H1
Yamaguchi, K1
Hironaka, S1
Shimada, K1
Hyodo, I1
Ohue, M1
Hamaguchi, T1
Sakai, D1
Noura, S1
Kinugasa, Y1
Fujita, S1
Shimada, Y1
Saito, N1
Moriya, Y1
Tang, Y1
Wang, W1
Teng, XZ1
Shi, L1
Chisaki, Y1
Noda, S1
Hira, D1
Morita, SY1
Yano, Y1
Terada, T1
Tanaka, H1
Mitsunaga, S1
Kobayashi, M1
Funazaki, H1
Katayama, S1
Kuwahara, A1
Okuyama, H1
Takahashi, H1
Ohno, I1
Shimizu, S1
Sakamoto, Y1
Kondo, S1
Ueno, H1
Ochiai, A1
Suzuki, S1
Honda, K1
Yamazaki, K1
Ishikawa, K1
Oyama, K2
Fushida, S2
Kaji, M2
Takeda, T2
Yabushita, K2
Nezuka, H1
Kinami, S2
Kadoya, N1
Takai, Y2
Tsukioka, Y1
Ohyama, S1
Tsuji, K1
Tsukada, T2
Kinoshita, J2
Fujimura, T2
Ohta, T2
Kasai, T1
Nakamura, Y1
Fukuda, M1
Kitazaki, T1
Nagashima, S1
Takatani, H1
Nakano, H1
Nakatomi, K1
Ikeda, T1
Tsukamoto, K1
Oka, M1
Kohno, S1
Arima, S1
Okamoto, T1
Toki, M1
Suzuki, Y1
Naruge, D1
Kawai, K1
Kobayashi, T1
Kasuga, A1
Kitamura, H1
Takasu, A1
Nagashima, F1
Sugiyama, M1
Park, I1
Lee, JL2
Ryu, MH1
Chang, HM1
Kim, TW2
Sym, SJ1
Lee, SS1
Jang, G1
Yoo, C1
Bae, KS1
Kang, YK1
Hong, YS1
Park, JH1
Kim, JH1
Yoon, SN1
Lim, SB1
Yu, CS1
Kim, MJ1
Jang, SJ1
Lee, JS1
Kim, JC1
Zhu, QC1
Jin, ZM1
Hirono, Y1
Yoshimoto, K1
Hirosawa, H1
Nakano, T1
Kimura, H1
Yasui, T1
Tsuneda, A1
Shirasaka, T1
Shimamoto, Y1
Kato, T1
Fukushima, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Single-arm, Multicenter, Phase II Clinical Study of the Efficacy and Safety of Carrilizumab Combinated With Gemcitabine and Oxaliplatin (GEMOX) as a Preoperative Translational Therapy for Unresectable Gallbladder Cancer[NCT05919095]Phase 237 participants (Anticipated)Interventional2023-06-30Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for oxonic acid and Vomiting

ArticleYear
[Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:3

    Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Diarrhea; Dogs; Drug Combinations; Female; Fluor

1998

Trials

11 trials available for oxonic acid and Vomiting

ArticleYear
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 12-01, Volume: 30, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deo

2019
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
    Oncotarget, 2017, Jun-06, Volume: 8, Issue:23

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat

2017
[Efficacy and safety of Xiaoaiping combined with chemotherapy in the treatment of advanced esophageal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2017, Jun-23, Volume: 39, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations;

2017
Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer.
    Cancer science, 2019, Volume: 110, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Dose-Respons

2019
A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis.
    International journal of clinical oncology, 2015, Volume: 20, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; A

2015
Efficacy of S-1 plus nedaplatin compared to standard second-line chemotherapy in EGFR-negative lung adenocarcinoma after failure of first-line chemotherapy.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-

2014
A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer.
    Chemotherapy, 2016, Volume: 61, Issue:2

    Topics: Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Dr

2016
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
    Anticancer research, 2017, Volume: 37, Issue:2

    Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Co

2017
Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:3

    Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relat

2010
Phase I study of preoperative chemoradiation with s-1 and oxaliplatin in patients with locally advanced resectable rectal cancer.
    International journal of radiation oncology, biology, physics, 2011, Mar-01, Volume: 79, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2011
[Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Colo

2011

Other Studies

7 other studies available for oxonic acid and Vomiting

ArticleYear
Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials.
    Pancreas, 2021, 08-01, Volume: 50, Issue:7

    Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Chemoradiotherapy; Clinical Trials as Topic; Drug C

2021
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
    British journal of cancer, 2017, Jun-06, Volume: 116, Issue:12

    Topics: Aftercare; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic;

2017
Reduction in gastrointestinal toxicity by gastric secretion inhibitors during S-1 monotherapy for patients with gastric cancer.
    Biological & pharmaceutical bulletin, 2014, Volume: 37, Issue:7

    Topics: Aged; Diarrhea; Dose-Response Relationship, Drug; Drug Combinations; Female; Gastric Mucosa; Histami

2014
[A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Female; Gastrointest

2015
Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck.
    Journal of chemotherapy (Florence, Italy), 2015, Volume: 27, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemot

2015
Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    International journal of clinical oncology, 2016, Volume: 21, Issue:3

    Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Ci

2016
Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Journal of gastroenterology, 2013, Volume: 48, Issue:11

    Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Ci

2013